NASDAQ · AUGX
Augmedix, Inc.
$2.35-$0.01 (-0.21%)
Augmedix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.48% below the high.
Loading market information…
NASDAQ · ICAD · USD
Stock price, earnings
Quote as of Jul 17, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
iCAD, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.49% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow iCAD, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
iCAD, Inc. specializes in delivering advanced solutions for cancer management, encompassing sophisticated image analysis tools, streamlined workflow optimization, and targeted radiation therapy. While primarily operating in the United States, the company also maintains a significant international presence. Its operations are organized into two principal divisions: Cancer Detection and Cancer Therapy. In the Cancer Detection segment, iCAD provides a range of innovative technologies. This includes the PowerLook platform, which serves as a central host for artificial intelligence algorithms and facilitates seamless communication between imaging acquisition devices, storage systems, and review platforms. Key diagnostic offerings feature SecondLook, a machine learning-driven algorithm designed to examine 2D full-field digital mammography images for identifying and marking suspicious masses and calcifications. Additionally, the company offers automated solutions for consistent and standardized assessment of breast density. Its portfolio further extends to ProFound AI, a deep-learning algorithm adept at detecting malignant soft-tissue densities and calcifications within digital breast tomosynthesis, and ProFound AI Risk, a tool that provides breast cancer risk estimation derived from screening mammograms. Magnetic resonance imaging (MRI) applications are also available for detecting breast and prostate cancer, along with VeraLook, a solution supporting the identification of colonic polyps in conjunction with CT Colonography. The Cancer Therapy division features the Xoft Axxent electronic brachytherapy systems. These systems are employed in the treatment of early-stage breast, non-melanoma skin, and gynecological cancers. Their clientele is diverse, spanning university research centers, community hospitals, specialized cancer care clinics, veterinary facilities, and dermatology practices. iCAD distributes its products through multiple channels, utilizing its own direct sales organizations, as well as collaborating with original equipment manufacturer (OEM) partners, various distributors, technology platform partners, and resellers. The company also has a global footprint, exporting its advanced technologies to regions including Europe, Taiwan, Canada, China, and other international markets. Originally established in 1984 under the name Howtek, Inc., the company was rebranded as iCAD, Inc. in June 2002. Its corporate headquarters are located in Nashua, New Hampshire.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:27 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Mar 12, 2024 | -$0.02+60.0% vs estimate | $4.74M+10.26% vs estimate |
|---|
| Q3 2023 | Nov 13, 2023 | -$0.04+55.56% vs estimate | $4.07M-5.28% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.35-$0.01 (-0.21%)
Augmedix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.48% below the high.
$0.77$0.00 (0.0%)
Genetic Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 78.69% below the high.
$20.65$0.00 (0.0%)
Opiant Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.52% below the high.
$3.02-$0.07 (-2.27%)
Cyteir Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.33% below the high.
$2.09-$0.01 (-0.48%)
HilleVax, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.69% below the high.
$2.94+$0.07 (+2.44%)
Five Star Senior Living Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.34% below the high.
$0.35+$0.00 (+0.64%)
Asensus Surgical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.87% below the high.
$30.03$0.00 (0.0%)
Neovasc Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.13% below the high.
